EDAP TMS SA announced the successful treatment of the first patient in its phase I/II PULS Trial, which is investigating the use of High Intensity Focused Ultrasound (HIFU) technology for pancreatic ...

THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing Sonovein®, a robotic platform for ...

AUSTIN, Texas, January 8, 2025 - EDAP TMS SA (EDAP), the global leader in robotic energy-based therapies, today announced that the first patient has been treated in a phase I/II PULS Trial sponsored ...

LYON, France, October 1, 2024 - EDAP TMS SA (EDAP), the global leader in robotic energy-based therapies, today announced that the first patients have been treated in a Phase I/II study evaluating the ...

Semi-Live Focal One Procedure to be Conducted on August 15th at 5:00 pm (KST) LYON, France, August 6, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today ...

John Wayne Cancer Institute (JWCI) at Providence Saint John’s Health Center is once again breaking new ground to benefit cancer patients. It has become the first medical center in the country to ...

Focal One's precision means qualifying prostate cancer patients can forego prostate removal surgery and avoid life-altering side effects including incontinence and impotence LYON, France - April 1, ...

Dublin, Aug. 04, 2020 (GLOBE NEWSWIRE) -- The "High Intensity Focused Ultrasound (HIFU) Market, Forecast by Application (Prostate Cancer, Neurological Disorder, Cosmetic Medicine, Uterine Fibroids), ...

Medical professionals have described the introduction of High-Intensity Focused Ultrasound (HIFU) technology for treating fibroids in Nigeria as a significant feat. The deployment of the technology by ...

The appointment of Joshua H. Levine to the Board of Directors brings significant executive experience and a proven track record of enhancing shareholder value in the medical technology sector. The ...

AUSTIN, Texas, January 8, 2025 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that the first patient has been treated in a phase I/II PULS Trial ...